| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| - | in-vitro, | CRC, | SW480 |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 4710- | CUR, | Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 1445- | Deg, | Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model |
| - | in-vivo, | lymphoma, | NA | - | in-vitro, | lymphoma, | NA |
| 1446- | Deg, | Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells |
| - | in-vitro, | BC, | 4T1 |
| 19- | Deg, | Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 1109- | DHA, | DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells |
| - | in-vitro, | BC, | NA |
| 5071- | dietSTF, | Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 1111- | EDM, | Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells |
| - | in-vitro, | Lung, | A549 |
| 1072- | EGCG, | Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways |
| - | in-vitro, | Thyroid, | 8505C |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 665- | EGCG, | Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway |
| - | in-vitro, | NA, | H1299 |
| 651- | EGCG, | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications |
| - | in-vitro, | PC, | NA |
| 4685- | EGCG, | Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines |
| - | in-vitro, | NPC, | TW01 | - | in-vitro, | NPC, | TW06 |
| 1247- | EMD, | Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 1319- | EMD, | Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling |
| - | in-vitro, | Thyroid, | TPC-1 | - | in-vitro, | Thyroid, | IHH4 |
| 2455- | erastin, | Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments |
| - | in-vitro, | Cerv, | HeLa |
| 1114- | F, | The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study |
| - | vitro+vivo, | NA, | NA |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 1655- | FA, | Ferulic acid inhibiting colon cancer cells at different Duke’s stages |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 1656- | FA, | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
| - | Review, | Var, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2840- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | NA, | CCA, | NA |
| 1113- | FIS, | Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| - | in-vitro, | Oral, | NA |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 806- | GAR, | Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin |
| - | vitro+vivo, | Pca, | HeLa | - | vitro+vivo, | Cerv, | SiHa |
| 817- | GAR, | Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways |
| - | vitro+vivo, | SCC, | KYSE150 | - | vitro+vivo, | SCC, | KYSE450 |
| 830- | GAR, | Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 1189- | Gb, | New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer |
| - | Review, | NA, | NA |
| 1186- | Gb, | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis |
| - | in-vitro, | PC, | NA | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | PC, | NA |
| 1116- | GI, | 6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT116 |
| 4505- | GLA, | Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α |
| - | in-vitro, | NSCLC, | Calu-1 |
| 858- | Gra, | Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 |
| 1118- | GSE, | Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | 5637 |
| 1240- | GSE, | PACs, | Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | Hs294T |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 1412- | HCA, | Identification of ATP Citrate Lyase as a Positive Regulator of Glycolytic Function in Glioblastomas |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 1087- | HNK, | Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H226 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:326 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid